Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0057 and Olaparib in Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
NCT02769962Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Apr 2023
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CRLX101 in small cell lung cancer (SCLC), urothelial carcinoma (UC), prostate cancer (PCa), solid tumor, sponsored by National Cancer Institute. Started May 2016; status: terminated.
02
Drugs
CRLX101
03
Conditions
small cell lung cancer (SCLC)urothelial carcinoma (UC)prostate cancer (PCa)solid tumor
Beyond the preview
Go deeper on NCT02769962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02769962.